Genotoxic profile of inhibitors of topoisomerases I (camptothecin) and II (etoposide) in a mitotic recombination and sex-chromosome loss somatic eye assay of Drosophila melanogaster.
Genotoxic carcinogens which interact with DNA may produce double-strand breaks as normal intermediates of homologous mitotic recombination, and may give rise to structural chromosome aberrations and inter-chromosomal deletion-recombination. The genotoxic profile of two inhibitors of DNA topoisomerases were evaluated using an in vivo somatic w/w+ eye assay of Drosophila melanogaster for the detection of loss of heterozygosity (LOH) by homologous mitotic recombination, intra-chromosomal recombination and structural chromosomal aberrations. We studied camptothecin (CPT) as a topoisomerase-I-interactive agent and etoposide (ETOP) as a topoisomerase II inhibitor. These drugs act by stabilizing a ternary complex consisting of topoisomerases covalently linked to DNA at single-strand or at double-strand breaks, thereby preventing the relegation step of the breakage/rejoining reaction mediated by the enzyme. The genotoxic profiles were determined from the appearance of eye tissue in adult flies, in which LOH and expression of the reporter gene white produced light clones. The results demonstrated that both compounds were significantly genotoxic, with CPT being more effective than ETOP. Inter-chromosomal mitotic recombination was the major mechanism responsible for the induction of light spots by both compounds in XX females. Loss of the ring X chromosome (rX), was significantly enhanced by CPT, and this topoisomerase blocker also produced intra-chromosomal recombination (XY males).
Sortibrán
América Nitxin Castañeda
AN
Laboratorio de Genética, Departamento de Biología Celular, Facultad de Ciencias, UNAM, Coyoacán, 04510 México D.F., Mexico.
Téllez
María Guadalupe Ordaz
MG
Rodríguez-Arnaiz
Rosario
R
D000818:Animals; D002166:Camptothecin / Q000633:toxicity*; D003433:Crosses, Genetic; D004331:Drosophila melanogaster / Q000235:genetics*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005047:Etoposide / Q000633:toxicity*; D005123:Eye / Q000166:cytology*; D005260:Female; D008297:Male; D008938:Mitosis / Q000187:drug effects*; D009153:Mutagens / Q000633:toxicity*; D011995:Recombination, Genetic / Q000187:drug effects; D012729:Sex Chromosome Aberrations / Q000187:drug effects*; D059004:Topoisomerase I Inhibitors
D004791:Enzyme Inhibitors; D009153:Mutagens; D059004:Topoisomerase I Inhibitors; D005047:Etoposide; D002166:Camptothecin